Marcel Rozencweig
About
In The Last Decade
Marcel Rozencweig
148 papers receiving 3.7k citations
Hit Papers
Peers
Comparison fields: 5 of 144
- Oncology 1.9k
- Molecular Biology 998
- Pulmonary and Respiratory Medicine 695
- Pathology and Forensic Medicine 598
- Cardiology and Cardiovascular Medicine 591
Countries citing papers authored by Marcel Rozencweig
This map shows the geographic impact of Marcel Rozencweig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcel Rozencweig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcel Rozencweig more than expected).
Fields of papers citing papers by Marcel Rozencweig
This network shows the impact of papers produced by Marcel Rozencweig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcel Rozencweig. The network helps show where Marcel Rozencweig may publish in the future.
Co-authorship network of co-authors of Marcel Rozencweig
This figure shows the co-authorship network connecting the top 25 collaborators of Marcel Rozencweig. A scholar is included among the top collaborators of Marcel Rozencweig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcel Rozencweig. Marcel Rozencweig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 75 | |
| 2 | 2 | |
| 3 | 5 | |
| 4 | 1 | |
| 5 | 42 | |
| 6 | The EORTC Clonogenic Assay Screening Study Group (CASSG) program. | 1 |
| 7 | 7 | |
| 8 | 3 | |
| 9 | Malignant lymphomas and Hodgkin's disease : experimental and therapeutic advances : proceedings of the Second International Conference on Malignant Lymphomas, Lugano, Switzerland, June 13-16, 1984 | 1 |
| 10 | New anticancer drugs : mitoxantrone and bisantrene | 32 |
| 11 | Étude en phase i de l'alizapride chez des patients cancéreux traites au cisplatine | 4 |
| 12 | New approaches in cancer therapy | 10 |
| 13 | Mitomycin C, current impact on cancer chemotherapy : proceedings of a Symposium on Mitomycin C presented during the Third NCI-EORTC Symposium on New Drugs in Cancer Therapy, Brussels, October 15-17, 1981 | 2 |
| 14 | International activities of the Division of Cancer Treatment, National Cancer Institute. | 1 |
| 15 | Lung cancer : progress in therapeutic research | 54 |
| 16 | Effective adjuvant treatments. A brief review of U.S. clinical trials. | 1 |
| 17 | Current trends and prospects in surgical adjuvant trials. | 2 |
| 18 | "Single"-agent activity of high-dose methotrexate with citrovorum factor rescue. | 10 |
| 19 | Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agents. | 13 |
| 20 | Breast cancer : trends in research and treatment | 27 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.